• Sun. Jan 24th, 2021

Dimancherouge

Technology

Abbott

  • Home
  • J.P. Morgan Analysts Reiterate Overweight Rating on Abbott Laboratories (ABT) and Raise Price Target Ahead of 3Q20 Earnings Release

J.P. Morgan Analysts Reiterate Overweight Rating on Abbott Laboratories (ABT) and Raise Price Target Ahead of 3Q20 Earnings Release

On Friday, J.P. Morgan analysts reiterated their Overweight rating on Abbott Laboratories (ABT) while raising their price target from $110 to $125. The analysts give their insight on what they…

Microfluidics Technology Market May See Big Move | Abbott Laboratories, Perkinelmer, Cepheid

A study published on Global Microfluidics Technology Market, includes exploratory survey, qualitative commentary on changing market dynamics with market sizing and estimates for 18+ Global Countries, business segments and applications.…

Analysts Reiterate Overweight Rating on Abbott Laboratories following European Approval of Freestyle Libre 3

On Monday, J.P. Morgan and Morgan Stanley reiterated their Overweight ratings on Abbott Laboratories (ABT). The company‚Äôs newest continuous glucose monitor (CGM), the Freestyle Libre 3, recently received a CE…

Vascular Stent Market 2020 New Innovations, Technology Progress- Abbott Laboratories, Boston Scientific Corporation

The MarketWatch News Department was not involved in the creation of this content. Global Vascular Stent Market Sep 29, 2020 (Market Insight Reports) — Vascular Stent Industry 2020 global market…